On June 11, Shares of SanDisk Corp. (NASDAQ:SNDK) are up 1.04% to $98.15 in pre-market trading this morning following a ratings upgrade to “buy” from “underperform” at Bank of Americ/Merrill Lynch. (BAC_) SanDisk Corporation (NASDAQ:SNDK) net profit margin is 18.10% and weekly performance is -1.54%. On last trading day company shares ended up $98.47. Analysts mean target price for the company is $102.71. SanDisk Corporation (NASDAQ:SNDK) distance from 50-day simple moving average (SMA50) is 11.79%.
Shares of Fusion-IO Inc (NYSE:FIO) have earned an average rating of “Hold” from the twenty-three ratings firms that are currently covering the company,StockRatingsNetwork.com reports. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $12.91. Fusion-IO, Inc. (NYSE:FIO) shares advanced 5.10% in last trading session and ended the day on $9.28. Gross Margin is 55.70% and its return on assets is -17.40%. Fusion-IO, Inc. (NYSE:FIO) quarterly performance is -19.72%.
On June 11, Stratasys Ltd. (NASDAQ:SSYS) a leading global provider of 3D printing and additive manufacturing solutions, announced that the company’s multi-materialObjet Connex 3D printing technology has played a leading role in the production of the iconic RoboCop suit created by Legacy Effects for the main character in this year’s blockbuster movie. Stratasys, Ltd. (NASDAQ:SSYS) shares moved up 1.63% in last trading session and was closed at $95.60, while trading in range of $93.53 – $96.02. Stratasys, Ltd. (NASDAQ:SSYS) year to date (YTD) performance is -29.03%.
Shares of bluebird bio Inc (NASDAQ:BLUE) jumped 64% in premarket trade Monday after the gene therapy company said that it had success treating two patients with an inherited blood disorder. The preliminary data on its gene therapy treatment, called LentiGlobin, showed that it was able to successfully replace non-functional genes with functional ones, leading to beneficial health results within two weeks. The company has begun another study that enrolls 15 patients. bluebird bio Inc (NASDAQ:BLUE) ended the last trading day at $ 26.09 . Company weekly volatility is calculated as 5.86% and price to cash ratio as 3.32. bluebird bio Inc (NASDAQ:BLUE) showed a positive weekly performance of 12.22%.
Williams Companies, Inc. (NYSE:WMB) the company that controls Williams Partners, agreed to buy control of Access Midstream from Global Infrastructure Partners II, Williams said in a statement. The combined companies would have a market value of about $36.9 billion. Williams Companies, Inc. (NYSE:WMB) net profit margin is 6.00% and weekly performance is -0.25%. On last trading day company shares ended up $47.18. Analysts mean target price for the company is $47.20. Williams Companies, Inc. (NYSE:WMB) distance from 50-day simple moving average (SMA50) is 8.33%.